Skip to main content
BioMed Research International logoLink to BioMed Research International
. 2019 Jan 29;2019:8515804. doi: 10.1155/2019/8515804

Corrigendum to “Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium”

Eckard Hamelmann 1,✉
PMCID: PMC6374813  PMID: 30834277

In the article titled “Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium” [1], there were errors in the description of Figure 1 and Table 1. The last sentence of Figure 1 should be updated from “LABA, long-acting β2-agonist” to “IL, interleukin; LABA, long-acting β2-agonist; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid; SABA, short-acting β2-agonist.” In addition, the last sentence of Table 1 should be updated from “LABA, long-acting β2-agonist; N/A, not applicable; NR, not reported; NS, not significant" to “ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; N/A, not applicable; NR, not reported.”

References

  • 1.Hamelmann E. Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium. BioMed Research International. 2018;2018:9. doi: 10.1155/2018/7473690.7473690 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BioMed Research International are provided here courtesy of Wiley

RESOURCES